Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


In Brief: Dr. Kremer's PMA

This article was originally published in The Gray Sheet

Executive Summary

Dr. Kremer's PMA: FDA Ophthalmic Devices Panel recommends against approval of a single-site premarket approval application sponsored by Frederic Kremer, MD, for a system to perform laser- assisted in situ keratomileusis. In a 4-2 vote, panel members cite poor patient accountability and inadequate standardization of post-operative patient evaluation. Kremer's PMA for the Laser-K laser-based system included data on 2,500 patients in two study cohorts. Uncorrected visual acuity at one-year follow-up was 92.2% for one group, 87.4% for the other cohort. The panel's rejection of the PMA likely will deal a blow to a licensing agreement between Kremer and Lasersight. Under the deal, Kremer must obtain a PMA approval allowing Lasersight to commercialize a LASIK system by July 28, or else the company can return the technology to Kremer...

You may also be interested in...

What Lies Ahead: COVID-19 Vaccination Challenges

The director of adult immunizations at Johns Hopkins International Vaccine Access Center talks to Scrip about undertaking a massive COVID-19 vaccination effort in the US.

P&G: Sales Growth Strongest When Rising Tide Floats All Competitors Across All Categories

P&G’s oral care business drove 35% of total category market growth in the firm’s fiscal 2020 and exemplifies its growth strategy for all segments – grow entire categories rather than take competitors’ market share, says CFO Jon Moeller.

COVID-19 Vaccine 'Brexit Bonus' A Myth

The Pink Sheet explains the procedures underpinning the UK’s emergency use authorization of the Pfizer/BioNTech COVID-19 vaccine.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts